Loading...
19 fluvoxamine COVID-19 controlled studies, 9 RCTs
42% improvement
for early treatment, RR
0.58
[0.31-1.08]
https://c19early.org/fmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
STOP COVID
Lenze (DB RCT)
93%
0.07 [0.01-0.52]
1,200mg
progression
0/80
6/72
Improvement, RR [CI]
Dose (4d)
Treatment
Control
STOP COVID
Lenze (DB RCT)
82%
0.18 [0.05-0.65]
1,200mg
hosp.
1/80
5/72
Seftel (QR)
84%
0.16 [0.01-3.29]
500mg
death/ICU
0/77
2/48
Seftel (QR)
94%
0.06 [0.01-0.37]
500mg
hosp.
0/77
6/48
Seftel (QR)
99%
0.01 [0.00-0.21]
500mg
no recov.
0/77
29/48
STOP COVID 2
Reiersen (DB RCT)
-201%
3.01 [0.12-73.6]
800mg
oxygen
1/272
0/275
STOP COVID 2
Reiersen (DB RCT)
33%
0.67 [0.24-1.87]
800mg
oxygen
6/272
9/275
STOP COVID 2
Reiersen (DB RCT)
38%
0.62 [0.16-2.46]
800mg
oxygen
3/164
6/205
STOP COVID 2
Reiersen (DB RCT)
9%
0.91 [0.38-2.20]
800mg
hosp.
9/272
10/275
STOP COVID 2
Reiersen (DB RCT)
12%
0.88 [0.42-1.81]
800mg
progression
13/272
15/275
Seo (SB RCT)
0%
1.00 [0.15-6.57]
800mg
progression
2/26
2/26
Seo (SB RCT)
34%
0.66 [0.06-6.73]
800mg
progression
1/19
2/25
Seo (SB RCT)
13%
0.87 [0.71-1.06]
800mg
progression
26 (n)
26 (n)
COVID-OUT
Bramante (DB RCT)
-11%
1.11 [0.33-3.61]
400mg
death/hosp.
6/329
5/324
OT1
COVID-OUT
Bramante (DB RCT)
-16%
1.16 [0.58-2.25]
400mg
progression
18/329
15/324
OT1
COVID-OUT
Bramante (DB RCT)
2%
0.98 [0.29-3.37]
400mg
hosp.
5/329
5/324
OT1
COVID-OUT
Bramante (DB RCT)
2%
0.98 [0.29-3.37]
400mg
hosp.
5/329
5/324
OT1
COVID-OUT
Bramante (DB RCT)
5%
0.95 [0.72-1.25]
400mg
progression
79/329
80/321
OT1
Pineda
94%
0.06 [0.01-0.52]
800mg
death
1/594
4/63
Pineda
73%
0.27 [0.14-0.54]
800mg
oxygen
15/594
13/63
Pineda
51%
0.49 [0.26-0.95]
800mg
hosp.
23/594
11/63
Pineda
-71%
1.71 [0.94-3.14]
800mg
hosp. time
23 (n)
11 (n)
Farahani (DB RCT)
51%
0.49 [0.24-1.02]
400mg
PASC
42 (n)
43 (n)
LONG COVID
Farahani (DB RCT)
44%
0.56 [0.23-1.37]
400mg
PASC
6/42
11/43
LONG COVID
Farahani (DB RCT)
62%
0.38 [0.11-1.35]
400mg
PASC
3/42
8/43
LONG COVID
Farahani (DB RCT)
52%
0.48 [0.25-0.95]
400mg
PASC
9/42
19/43
LONG COVID
Farahani (DB RCT)
49%
0.51 [0.14-1.91]
400mg
PASC
3/42
6/43
LONG COVID
Farahani (DB RCT)
59%
0.41 [0.08-2.00]
400mg
PASC
2/42
5/43
LONG COVID
Farahani (DB RCT)
-17%
1.17 [0.47-2.94]
400mg
PASC
8/42
7/43
LONG COVID
Farahani (DB RCT)
8%
0.92 [0.42-2.04]
400mg
PASC
9/42
10/43
LONG COVID
Farahani (DB RCT)
74%
0.26 [0.03-2.20]
400mg
PASC
1/42
4/43
LONG COVID
Farahani (DB RCT)
85%
0.15 [0.02-1.14]
400mg
PASC
1/42
7/43
LONG COVID
Farahani (DB RCT)
37%
0.63 [0.29-1.36]
400mg
PASC
8/42
13/43
LONG COVID
Farahani (DB RCT)
27%
0.73 [0.25-2.12]
400mg
PASC
5/42
7/43
LONG COVID
Farahani (DB RCT)
6%
0.94 [0.75-1.17]
400mg
PASC
32/42
35/43
LONG COVID
TOGETHER
Reis (DB RCT)
-200%
3.00 [0.12-73.5]
800mg
death
1/738
0/738
CT2
TOGETHER
Reis (DB RCT)
12%
0.88 [0.32-2.40]
800mg
hosp.
7/738
8/738
CT2
TOGETHER
Reis (DB RCT)
50%
0.50 [0.25-0.92]
800mg
progression
13/738
27/738
CT2
EFFaCo
Siripongbo.. (RCT)
-2%
1.02 [0.26-4.00]
400mg
oxygen
4/162
4/165
EFFaCo
Siripongbo.. (RCT)
-22%
1.22 [0.38-3.93]
400mg
hosp.
6/162
5/165
Tsiakalos
67%
0.33 [0.01-7.84]
800mg
ICU
0/53
1/50
Tsiakalos
84%
0.16 [0.02-1.26]
800mg
hosp.
1/53
6/50
Tsiakalos
86%
0.14 [0.02-0.74]
800mg
progression
2/53
8/50
TOGETHER
Reis (DB RCT)
30%
0.70 [0.37-1.26]
800mg
death
17/741
25/756
TOGETHER
Reis (DB RCT)
91%
0.09 [0.01-0.47]
800mg
death
1/548
12/618
TOGETHER
Reis (DB RCT)
22%
0.78 [0.46-1.28]
800mg
ventilation
26/741
34/756
TOGETHER
Reis (DB RCT)
22%
0.78 [0.61-1.03]
800mg
hosp.
75/741
97/756
TOGETHER
Reis (DB RCT)
32%
0.68 [0.52-0.88]
800mg
hosp./ER
79/741
119/756
TOGETHER
Reis (DB RCT)
31%
0.69 [0.53-0.90]
800mg
hosp./ER
78/740
115/752
TOGETHER
Reis (DB RCT)
66%
0.34 [0.21-0.54]
800mg
hosp./ER
541 (n)
609 (n)
TOGETHER
Reis (DB RCT)
-49%
1.49 [0.94-2.38]
800mg
viral+
167/207
163/221
Calusic (ICU)
42%
0.58 [0.36-0.94]
1,200mg
death
30/51
39/51
ICU patients
Kirenga
68%
0.32 [0.19-0.53]
800mg
death
29/94
126/222
Kirenga
53%
0.47 [0.23-0.97]
800mg
recovery
94 (n)
222 (n)
ACTIV-6
Naggie (DB RCT)
31%
0.69 [0.27-1.21]
700mg
progression
14/589
21/586
ACTIV-6
Naggie (DB RCT)
34%
0.66 [0.23-1.16]
700mg
clin. ord.
589 (n)
586 (n)
ACTIV-6
Naggie (DB RCT)
-15%
1.15 [0.51-1.83]
700mg
clin. ord.
589 (n)
586 (n)
ACTIV-6
Naggie (DB RCT)
6%
0.94 [0.29-1.74]
700mg
clin. ord.
589 (n)
586 (n)
ACTIV-6
Naggie (DB RCT)
-1%
1.01 [0.92-1.12]
700mg
no recov.
589 (n)
586 (n)
ACTIV-6
Naggie (DB RCT)
49%
0.51 [0.05-5.64]
700mg
hosp.
1/589
2/586
Oskotsky (PSM)
-58%
1.58 [0.42-5.93]
n/a
death
2/11
19/165
Oskotsky (PSM)
26%
0.74 [0.55-0.99]
n/a
death
48/481
956/7,215
Fritz
19%
0.81 [0.26-2.22]
n/a
hosp./ER
4/17
1,896/20,457
Fritz
12%
0.88 [0.79-0.99]
n/a
hosp./ER
707/3,414
1,896/20,457
Fritz
12%
0.88 [0.77-0.99]
n/a
hosp./ER
559/2,744
1,896/20,457
Fritz
10%
0.90 [0.81-0.99]
n/a
hosp./ER
971/4,577
1,896/20,457
Diaz (PSM)
28%
0.72 [0.63-0.81]
n/a
cases
4,558 (n)
4,558 (n)
Trkulja (PSM)
27%
0.73 [0.35-1.55]
n/a
death
Trkulja (PSM)
-37%
1.37 [0.56-3.33]
n/a
hosp.
Visos-Varela
-103%
2.03 [0.24-17.4]
n/a
death
case control
Visos-Varela
-395%
4.95 [0.34-71.4]
n/a
ICU
case control
Visos-Varela
40%
0.60 [0.19-1.92]
n/a
hosp.
case control
Visos-Varela
32%
0.68 [0.18-2.50]
n/a
progression
case control
Visos-Varela
12%
0.88 [0.54-1.43]
n/a
cases
case control
Fluvoxamine COVID-19 outcomes
c19 early .org
October 2023
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors fluvoxamine
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit